Novartis Achieves Milestone with FDA's Initial Approval for Oral BTK Inhibitor Targeting Chronic Urticaria

Novartis Achieves Milestone with FDA’s Initial Approval for Oral BTK Inhibitor Targeting Chronic Urticaria